이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hisamitsu Pharmaceutical 관리

관리 기준 확인 2/4

Hisamitsu Pharmaceutical's CEO는 Kazuhide Nakatomi, May2015 에 임명되었습니다 의 임기는 9.08 년입니다. 는 ¥ 898.78M 가치에 해당하는 회사 주식의 0.33% 직접 소유합니다. 898.78M. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 10.1 년입니다.

주요 정보

Kazuhide Nakatomi

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	9.1yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	6.1yrs
이사회 평균 재임 기간	10.1yrs

최근 관리 업데이트

Recent updates

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Jun 13

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Apr 09

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Mar 18

CEO

Kazuhide Nakatomi (52 yo)

9.1yrs

테뉴어

Mr. Kazuhide Nakatomi serves as the President of Hisamitsu Pharmaceutical Co. Inc. since May 2015 and has been Chief Executive Officer since May 2019 and has been Director since May 2007 and served as its...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kazuhide Nakatomi	President	9.1yrs	데이터 없음	0.33% ¥ 910.7m
Nobuo Tsutsumi	GM of Legal Dept	10.1yrs	데이터 없음	0.0068% ¥ 18.6m
Kazunori Ito	Executive Officer & GM of Human Resources Department	no data	데이터 없음	데이터 없음
Kyu Saito	MD, Executive Officer	no data	데이터 없음	0.0095% ¥ 26.0m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	no data	데이터 없음	0.0082% ¥ 22.3m
Mitsutoshi Tsuruta	Executive Officer & Head of Ethical Division	no data	데이터 없음	데이터 없음
Masaya Okuno	Executive Officer and Head of Sales & Marketing Division	no data	데이터 없음	데이터 없음
Koji Takiyama	Executive Officer	3.1yrs	데이터 없음	0.0041% ¥ 11.2m
Katsuhiko Akiyama	Sr. Exe. Officer & GM of MN Commercialization Office	1.4yrs	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: 4530 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kazuhide Nakatomi	President	17.1yrs	데이터 없음	0.33% ¥ 910.7m
Nobuo Tsutsumi	GM of Legal Dept	10.1yrs	데이터 없음	0.0068% ¥ 18.6m
Kyu Saito	MD, Executive Officer	11.1yrs	데이터 없음	0.0095% ¥ 26.0m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	10.1yrs	데이터 없음	0.0082% ¥ 22.3m
Koji Takiyama	Executive Officer	3.1yrs	데이터 없음	0.0041% ¥ 11.2m
Munehiko Hirano	Standing Corporate Auditor	18.1yrs	데이터 없음	0.0027% ¥ 7.4m
Nobuyuki Nakatomi	Standing Corporate Auditor	16.1yrs	데이터 없음	0.34% ¥ 929.2m
Keinosuke Ono	Part-time Outside Corporate Auditor	no data	데이터 없음	0.0027% ¥ 7.4m
Tetsugo Matsuo	Part-time Outside Independent Director	4.1yrs	데이터 없음	0.0014% ¥ 3.7m
Teijiro Furukawa	Independent Outside Director	9.1yrs	데이터 없음	데이터 없음
Yuichiro Anzai	Part-time Outside Independent Director	4.1yrs	데이터 없음	데이터 없음
Tamako Watanabe	Part Time Outside Independent Director	1.1yrs	데이터 없음	데이터 없음

10.1yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: 4530 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.1 년).

Hisamitsu Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Price target decreased by 15% to JP¥4,250

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

Price target increased by 16% to JP¥4,450

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥42.25 per share at 2.1% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Less than half of directors are independent

Price target increased to JP¥3,700

Consensus forecasts updated

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Consensus EPS estimates fall by 19%

Price target decreased to JP¥3,600

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)

Hisamitsu Pharmaceutical Co., Inc. Provides Earnings Guidance for the Year Ending February 28, 2022

Upcoming Dividend of JP¥41.75 Per Share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2021 Results on Apr 08, 2021

New 90-day high: JP¥6,430

Revenue and earnings miss expectations

Revenue and earnings miss expectations

Third quarter 2021 earnings released: EPS JP¥24.82

New 90-day high: JP¥6,370

New 90-day high: JP¥6,340

New 90-day high: JP¥6,230

Price target lowered to JP¥4,400

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2021 Results on Jan 13, 2021

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2021 Results on Oct 08, 2020

CEO

테뉴어

리더십 팀